3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
630
Triple Negative Breast Neoplasms
166
Ovarian Neoplasms
103
Carcinoma, Non-Small-Cell Lung
100
Neoplasm Metastasis
76
Colorectal Neoplasms
64
Melanoma
61
Stomach Neoplasms
60
Neoplasms
56
Pancreatic Neoplasms
55
Squamous Cell Carcinoma of Head and Neck
50
Prostatic Neoplasms
48
Endometrial Neoplasms
48
Lung Neoplasms
47
Uterine Cervical Neoplasms
36
Carcinoma, Renal Cell
35
Sarcoma
33
Head and Neck Neoplasms
33
Esophageal Neoplasms
32
Breast Neoplasms, Male
29
Urinary Bladder Neoplasms
26
Small Cell Lung Carcinoma
26
Colonic Neoplasms
26
Carcinoma, Transitional Cell
23
Carcinoma, Ovarian Epithelial
21
Lymphoma
18
Brain Neoplasms
18
Kidney Neoplasms
17
Carcinoma, Hepatocellular
17
Liver Neoplasms
15
Interventions
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Triple Negative Locally Advanced Non-resectable Breast Cancer
×
Breast
×
Clear all
NCT06827613
2025-09-24
START-002
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
50 enrolled